Condition
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Not Yet Recruiting2
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06647979Phase 1Recruiting
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
NCT06743113Not ApplicableNot Yet Recruiting
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT07175051Phase 2Not Yet RecruitingPrimary
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
NCT01960413Phase 2CompletedPrimary
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Showing all 4 trials